tiprankstipranks
Elevation Oncology Announces Preliminary Phase 1 Trial Results
Company Announcements

Elevation Oncology Announces Preliminary Phase 1 Trial Results

Don't Miss Our Christmas Offers:

The latest announcement is out from Elevation Oncology (ELEV).

Elevation Oncology will hold a conference call and webcast on August 6, 2024, to present preliminary results from their Phase 1 trial of EO-3021. Interested parties can find the presentation materials on the investor relations section of their website. The materials provided, however, are not considered part of this legal filing and will not be filed under the Exchange Act or integrated into other filings, except where explicitly referenced.

For detailed information about ELEV stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyElevation Oncology nominates EO-1022 as its HER3 ADC development candidate
TheFlyElevation Oncology enters licensing agreement with Synaffix B.V.
TheFlyElevation Oncology presents positive Phase 1 results of EO-3021 combination
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App